论文部分内容阅读
目的:探讨国产吉西他滨联合卡铂方案对晚期非小细胞肺癌的疗效。方法:经病理学证实的35例初治晚期非小细胞肺癌患者采用吉西他滨(1000mg/m2,d1、8),卡铂(4~5mg/ml·min曲线下面积,d1),21d为1个化疗周期。结果:完全缓解(CR)2例,部分缓解(PR)15例,总有效率48.6%,鳞癌有效率最高(57.9%),腺癌有效率次之(42.9%),二者差异不显著,大细胞癌和类癌均无效。主要毒性反应为骨髓抑制导致的白细胞和血小板减少,消化道反应极轻微。结论:吉西他滨联合卡铂对晚期非小细胞肺癌疗效明确,不良反应小,耐受性好。
Objective: To investigate the efficacy of domestic gemcitabine combined with carboplatin in the treatment of advanced non-small cell lung cancer. Methods: 35 cases of newly diagnosed advanced non-small cell lung cancer confirmed by pathology were treated with gemcitabine (1000mg / m2, d1,8) and carboplatin (area under the curve of 4 ~ 5mg / ml · min, d1) Chemotherapy cycle. Results: There were 2 cases of complete remission (CR), 15 cases of partial remission (PR), the total effective rate was 48.6%, the highest effective rate of squamous cell carcinoma (57.9%) and the second highest effective rate of adenocarcinoma (42.9%), the difference was insignificant , Large cell carcinoma and carcinoid are ineffective. The main toxicity is myelosuppression caused by leukopenia and thrombocytopenia, gastrointestinal reaction is minimal. Conclusion: Gemcitabine plus carboplatin is effective in treating advanced non-small cell lung cancer with small adverse reactions and good tolerability.